What are the differential diagnoses for a patient with symptoms suggestive of hypermobility-type Ehlers-Danlos syndrome?

Differential Diagnosis for Hypermobile Ehlers-Danlos Syndrome

When evaluating a patient with suspected hypermobile Ehlers-Danlos syndrome (hEDS), the most critical differential diagnoses to systematically exclude are Marfan syndrome, other EDS subtypes (particularly classic, vascular, and kyphoscoliotic types), Loeys-Dietz syndrome, osteogenesis imperfecta, and other heritable connective tissue disorders—this exclusion is mandatory before confirming hEDS diagnosis. 1, 2

Primary Differential Diagnoses Requiring Exclusion

Marfan Syndrome (MFS)

The key distinguishing feature is that joint hypermobility in hEDS mimics that in MFS, but MFS presents with ectopia lentis (lens dislocation), aortic root dilation, and specific skeletal features 1. Critical differentiating points:

• Skin findings: In hEDS, skin is soft/velvety with mild hyperextensibility; in MFS, skin is rarely hyperextensible 1
• Ocular manifestations: Ectopia lentis is diagnostic for MFS and absent in hEDS
• Cardiovascular: While mild aortic root dilation occurs in 25-33% of hEDS patients, significant dilation with dissection risk is characteristic of MFS 1
• Required evaluation: Dilated eye exam and echocardiogram are mandatory to exclude MFS 1

Other EDS Subtypes

Classic EDS: Distinguished by significant skin hyperextensibility, atrophic scarring, and skin fragility—features that should be absent in hEDS 1. The presence of skin or soft tissue fragility suggests classic or other EDS subtypes rather than hEDS.

Vascular EDS: This is a critical exclusion due to life-threatening implications. Look for thin, translucent skin with visible veins, easy bruising with extensive hematomas, and arterial/organ rupture 3, 4. Any suspicion of vascular involvement (aneurysms, dissection) mandates genetic testing for COL3A1 mutations 3.

Kyphoscoliotic EDS: Characterized by severe progressive kyphoscoliosis from birth, muscle hypotonia, and ocular fragility 2, 5.

Loeys-Dietz Syndrome (LDS)

Presents with arterial tortuosity, aneurysms at smaller diameters than MFS, and distinctive craniofacial features (hypertelorism, bifid uvula, cleft palate) 2, 4. Genetic testing for TGFBR1/TGFBR2 mutations is indicated when arterial involvement is present 4.

Osteogenesis Imperfecta (OI)

Joint hypermobility with bone fragility, recurrent fractures, blue sclerae, and dentinogenesis imperfecta distinguish OI from hEDS 2, 6.

Secondary Differential Diagnoses

Neuromuscular Disorders with Joint Hypermobility

Several congenital myopathies present with joint hypermobility and mild-to-moderate muscle weakness 5:

• Collagen VI-related dystrophies: Muscle weakness with joint contractures or hypermobility
• RYR1-related myopathy: Prominent joint hypermobility with muscle weakness
• SEPN1-related myopathy: Congenital myopathy with hypermobility features

Clinical pitfall: These represent the same spectrum of extracellular matrix disorders and require muscle biopsy or genetic testing for differentiation 5.

Familial Thoracic Aortic Aneurysm and Dissection (FAA)

Autosomal dominant predisposition to thoracic aortic aneurysms without other connective tissue features. Some patients may have mild skeletal changes (pectus excavatum, scoliosis) overlapping with hEDS 1.

Hypermobility Spectrum Disorders (HSDs)

Patients with symptomatic joint hypermobility who do not meet all three diagnostic criteria for hEDS fall into this category 7. This is essentially a diagnosis for those with features suggestive of but not fully meeting hEDS criteria.

Systematic Diagnostic Approach

Step 1: Confirm Joint Hypermobility

Use the Beighton scale ≥5/9 points as the objective measure 1:

• Fifth finger dorsiflexion >90° (2 points)
• Thumb to forearm apposition (2 points)
• Elbow hyperextension >10° (2 points)
• Knee hyperextension >10° (2 points)
• Forward flexion with palms flat on floor (1 point)

Step 2: Assess Skin and Tissue Characteristics

• hEDS: Soft, velvety skin with normal or slightly increased extensibility; no fragility
• Classic EDS: Marked hyperextensibility with atrophic scarring
• Vascular EDS: Thin, translucent skin with visible veins
• Absence of skin/soft tissue fragility is mandatory for hEDS diagnosis 1

Step 3: Mandatory Exclusion Testing

All patients require 1:

1. Echocardiogram: To evaluate aortic root diameter and exclude MFS/LDS
2. Dilated eye examination: To exclude ectopia lentis (MFS) and other ocular abnormalities
3. Detailed family history: Autosomal dominant pattern suggests hEDS; history of arterial dissection/rupture suggests vascular EDS or LDS

Step 4: Genetic Testing Considerations

Genetic testing identified alternative diagnoses in 26.4% of patients meeting clinical hEDS criteria 8. Consider genetic testing when:

• Cardiovascular involvement is present (echocardiogram abnormalities)
• Skin findings suggest classic or vascular EDS
• Atypical features or severe manifestations are present
• Family history suggests other heritable connective tissue disorders
• A small subset of hEDS has TNXB gene mutations 1

Step 5: Evaluate for Associated Conditions

Once hEDS is confirmed, assess for commonly associated conditions that may influence management 9, 7:

• Postural Orthostatic Tachycardia Syndrome (POTS): Orthostatic intolerance symptoms
• Mast Cell Activation Syndrome (MCAS): Multisystem symptoms triggered by foods, temperature, stress
• Gastrointestinal disorders: 98% of hEDS patients meet criteria for disorders of gut-brain interaction 9
• Chronic pain syndromes
• Anxiety disorders

Critical Clinical Pitfalls

1. Do not diagnose hEDS without excluding other conditions: The diagnosis is one of exclusion 1, 2
2. Do not assume normal echocardiogram rules out all cardiovascular risk: 25-33% of hEDS patients develop mild aortic root dilation over time; surveillance is required 1
3. Do not overlook vascular EDS: Missing this diagnosis can be fatal; thin translucent skin and arterial complications mandate COL3A1 testing 3
4. Do not dismiss neuromuscular symptoms: Muscle weakness with hypermobility suggests myopathy, not hEDS 5
5. Recognize intrafamilial variability: Even within families with confirmed genetic diagnoses, phenotypic expression varies significantly 6

When Genetic Testing Changes Management

Genetic testing is not just confirmatory—it fundamentally alters surveillance and management 8, 6:

• Vascular EDS: Requires annual vascular imaging, strict blood pressure control, avoidance of contact sports
• Cardiac valvular EDS: Mandates cardiologic monitoring
• Combined OI/EDS: Necessitates fracture-preventive measures
• Brittle cornea syndrome: Requires early ophthalmologic intervention

The absence of a known genetic mutation does not exclude hEDS, as the molecular basis remains unknown 1, 7. However, finding an alternative genetic diagnosis occurs frequently enough (26.4% in one series) that genetic testing should be strongly considered in the diagnostic workup 8.